Summit Therapeutics (LON:SUMM) issued its quarterly earnings data on Wednesday. The company reported GBX (3) (($0.04)) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of GBX (10.10) (($0.14)) by GBX 7.10 ($0.10), Bloomberg Earnings reports. The company had revenue of £173 million for the quarter.
Shares of Summit Therapeutics (SUMM) opened at GBX 180 ($2.42) on Wednesday. Summit Therapeutics has a 1-year low of GBX 138.14 ($1.86) and a 1-year high of GBX 269.70 ($3.63).
SUMM has been the topic of a number of recent research reports. N+1 Singer reissued a “corporate” rating on shares of Summit Therapeutics in a report on Tuesday, November 7th. reissued a “corporate” rating on shares of Summit Therapeutics in a report on Tuesday, November 7th.
About Summit Therapeutics
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
What are top analysts saying about Summit Therapeutics PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Summit Therapeutics PLC and related companies.